UniProt P21802 · PDB · AlphaFold · Substrate: pEY + Mn · Clone: cytoplasmic
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Ponatinib | 99.4% | 0.6% | 78.23 | 0.534 |
| 2 | Futibatinib | 99.3% | 0.7% | 98.48 | 0.718 |
| 3 | Erdafitinib | 99.0% | 1.0% | 95.71 | 0.737 |
| 4 | Alpelisib | 98.9% | 1.1% | 97.22 | 0.720 |
| 5 | Infigratinib | 98.8% | 1.2% | 98.24 | 0.710 |
| 6 | Pemigatinib | 98.7% | 1.3% | 98.23 | 0.718 |
| 7 | Nintedanib | 97.0% | 3.0% | 90.23 | 0.608 |
| 8 | Axitinib | 96.1% | 3.9% | 93.23 | 0.688 |
| 9 | Brigatinib | 96.1% | 3.9% | 82.96 | 0.513 |
| 10 | Tenalisib | 96.0% | 4.0% | 97.98 | 0.702 |
| 11 | Selpercatinib | 95.0% | 5.0% | 96.72 | 0.635 |
| 12 | Pralsetinib | 93.2% | 6.8% | 93.43 | 0.643 |
| 13 | Deucravacitinib | 92.5% | 7.5% | 98.99 | 0.718 |
| 14 | Vandetanib | 90.8% | 9.2% | 95.74 | 0.723 |
| 15 | Pazopanib | 88.9% | 11.1% | 97.49 | 0.672 |
| 16 | Midostaurin | 86.1% | 13.9% | 78.64 | 0.500 |
| 17 | Ripretinib | 85.4% | 14.6% | 92.95 | 0.674 |
| 18 | Lenvatinib | 85.4% | 14.6% | 97.74 | 0.726 |
| 19 | Entrectinib | 81.5% | 18.5% | 93.69 | 0.671 |
| 20 | Repotrectinib | 79.8% | 20.2% | 84.21 | 0.608 |
Paralog block
FGFR1, FGFR2, FGFR3, FGFR4
EMT expression
- Mesenchymal log2(TPM+1): 1.07
- Epithelial log2(TPM+1): 2.42
- Fold change: -1.35
- Status: Downregulated
Selectivity landscape vs inhibition on FGFR2
Each point is one of the 92 approved drugs; color = inhibition % on FGFR2.
Mutation lollipop
Cancer-associated mutations plotted by residue position. Marker size + color scale with the number of distinct cancer reports.
Variants (18)
FGFR2 (C491A)
point
FGFR2 (C491A/V564I)
compound
FGFR2 (C491A/V564L)
compound
FGFR2 (C491F)
point
FGFR2 (C491S)
point
FGFR2 (C491S/V564L)
compound
FGFR2 (E565A)
point
FGFR2 (E565G)
point
FGFR2 (K526E)
point
FGFR2 (K641R)
point
FGFR2 (K659N)
point
FGFR2 (M420I)
point
FGFR2 (N549H)
point
FGFR2 (N549K)
point
FGFR2 (R612T)
point
FGFR2 (V564F)
point
FGFR2 (V564I)
point
FGFR2 (V564L)
point
Mutation × cancer associations
| Mutation | Cancer | Organ | Source |
|---|---|---|---|
| E565A | carcinoma_biliary_tract | Biliary Tract | ref |
| C491A | endometrial_carcinoma | Uterus | ref |
| C491A | carcinoma_liver | Liver | ref |
| C491F | endometrial_carcinoma | Uterus | ref |
| C491F | carcinoma_liver | Liver | ref |
| C491S | endometrial_carcinoma | Uterus | ref |
| C491S | carcinoma_liver | Liver | ref |
| E565G | endometrial_carcinoma | Uterus | ref |
| E565G | carcinoma_liver | Liver | ref |
| K526E | endometrial_carcinoma | Uterus | ref |
| K526E | carcinoma_liver | Liver | ref |
| M420I | endometrial_carcinoma | Uterus | ref |
| M420I | carcinoma_liver | Liver | ref |
| V564I | endometrial_carcinoma | Uterus | ref |
| V564I | carcinoma_liver | Liver | ref |
| V564L | endometrial_carcinoma | Uterus | ref |
| V564L | carcinoma_liver | Liver | ref |
| K641R | carcinoma_biliary_tract | Biliary Tract | ref |
| K641R | carcinoma_salivary_gland | Salivary Gland | ref |
| K659N | carcinoma_breast | Breast | ref |
| K659N | carcinoma_lung | Lung | ref |
| K659N | carcinoma_urinary_tract | Bladder | ref |
| K659N | carcinoma_endometrium | Uterus | ref |
| K659N | BLCA-US | Bladder | ref |
| K659N | LUSC-US | Lung | ref |
| N549H | carcinoma_biliary_tract | Biliary Tract | ref |
| N549H | carcinoma_endometrium | Uterus | ref |
| N549H | carcinoma_urinary_tract | Bladder | ref |
| N549H | carcinoma_ovary | Ovary | ref |
| N549H | adnexal_tumour_skin | Skin | ref |
Showing 30 of 54 associations.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…